{
    "organizations": [],
    "uuid": "773aae3e31a43aaf47398a5fd441121866d93219",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/12/globe-newswire-catalyst-pharmaceuticals-announces-date-and-time-change-for-fourth-quarter-and-year-end-financial-results-call-and-webcast.html",
    "ord_in_thread": 0,
    "title": "Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CORAL GABLES, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has changed the date for its fourth quarter and year-end financial results conference call and webcast. Catalyst will now host its conference call to discuss the financial results and to provide a corporate update at 5:00 p.m. ET on Wednesday, March 14, 2018. The conference call was previously scheduled for Thursday, March 15 th at 8:30 a.m. ET.\nThe adjustment is being made to accommodate scheduling conflicts during the originally scheduled time. As previously announced, fourth quarter and year-end 2017 financial results will be released after the market closes on Wednesday, March 14, 2018.\nInvestors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page.\nA webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com .\nAbout Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.\nCatalyst is also developing CPP-115 to treat refractory infantile spasms. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).\nForward-Looking Statements\nThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.\nInvestor Contact Brian Korb The Trout Group LLC (646) 378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com\nSource:Catalyst Pharmaceuticals, Inc.",
    "published": "2018-03-12T15:03:00.000+02:00",
    "crawled": "2018-03-12T15:40:33.032+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "coral",
        "gable",
        "march",
        "globe",
        "newswire",
        "catalyst",
        "pharmaceutical",
        "nasdaq",
        "cprx",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "commercializing",
        "innovative",
        "therapy",
        "people",
        "rare",
        "debilitating",
        "chronic",
        "neuromuscular",
        "neurological",
        "disease",
        "today",
        "announced",
        "changed",
        "date",
        "fourth",
        "quarter",
        "financial",
        "result",
        "conference",
        "call",
        "webcast",
        "catalyst",
        "host",
        "conference",
        "call",
        "discus",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "et",
        "wednesday",
        "march",
        "conference",
        "call",
        "previously",
        "scheduled",
        "thursday",
        "march",
        "th",
        "et",
        "adjustment",
        "made",
        "accommodate",
        "scheduling",
        "conflict",
        "originally",
        "scheduled",
        "time",
        "previously",
        "announced",
        "fourth",
        "quarter",
        "financial",
        "result",
        "released",
        "market",
        "close",
        "wednesday",
        "march",
        "investor",
        "wish",
        "participate",
        "conference",
        "call",
        "may",
        "dialing",
        "domestic",
        "canadian",
        "caller",
        "international",
        "caller",
        "interested",
        "listening",
        "conference",
        "call",
        "live",
        "via",
        "internet",
        "may",
        "visiting",
        "investor",
        "page",
        "company",
        "website",
        "clicking",
        "webcast",
        "link",
        "investor",
        "home",
        "page",
        "webcast",
        "replay",
        "available",
        "catalyst",
        "website",
        "day",
        "following",
        "call",
        "visiting",
        "investor",
        "page",
        "company",
        "website",
        "catalyst",
        "pharmaceutical",
        "catalyst",
        "pharmaceutical",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "commercializing",
        "innovative",
        "therapy",
        "people",
        "rare",
        "debilitating",
        "chronic",
        "neuromuscular",
        "neurological",
        "disease",
        "including",
        "myasthenic",
        "syndrome",
        "lem",
        "congenital",
        "myasthenic",
        "syndrome",
        "cm",
        "musk",
        "antibody",
        "positive",
        "myasthenia",
        "gravis",
        "infantile",
        "spasm",
        "received",
        "breakthrough",
        "therapy",
        "designation",
        "food",
        "drug",
        "administration",
        "fda",
        "treatment",
        "lem",
        "orphan",
        "drug",
        "designation",
        "lem",
        "cm",
        "myasthenia",
        "gravis",
        "firdapse",
        "first",
        "approved",
        "drug",
        "europe",
        "symptomatic",
        "treatment",
        "adult",
        "lem",
        "catalyst",
        "also",
        "developing",
        "treat",
        "refractory",
        "infantile",
        "spasm",
        "granted",
        "orphan",
        "drug",
        "designation",
        "treatment",
        "infantile",
        "spasm",
        "fda",
        "granted",
        "orphan",
        "medicinal",
        "product",
        "designation",
        "treatment",
        "west",
        "syndrome",
        "european",
        "commission",
        "addition",
        "catalyst",
        "developing",
        "generic",
        "version",
        "vigabatrin",
        "statement",
        "press",
        "release",
        "contains",
        "statement",
        "statement",
        "involve",
        "known",
        "unknown",
        "risk",
        "uncertainty",
        "may",
        "cause",
        "catalyst",
        "actual",
        "result",
        "future",
        "period",
        "differ",
        "materially",
        "forecasted",
        "result",
        "number",
        "factor",
        "including",
        "factor",
        "described",
        "catalyst",
        "annual",
        "report",
        "form",
        "fiscal",
        "year",
        "filing",
        "security",
        "exchange",
        "commission",
        "sec",
        "could",
        "adversely",
        "affect",
        "catalyst",
        "copy",
        "catalyst",
        "filing",
        "sec",
        "available",
        "sec",
        "may",
        "found",
        "catalyst",
        "website",
        "may",
        "obtained",
        "upon",
        "request",
        "catalyst",
        "catalyst",
        "undertake",
        "obligation",
        "update",
        "information",
        "contained",
        "herein",
        "speaks",
        "date",
        "investor",
        "contact",
        "brian",
        "korb",
        "trout",
        "group",
        "llc",
        "bkorb",
        "company",
        "contact",
        "patrick",
        "mcenany",
        "catalyst",
        "pharmaceutical",
        "chief",
        "executive",
        "officer",
        "pmcenany",
        "medium",
        "contact",
        "david",
        "schull",
        "russo",
        "partner",
        "source",
        "catalyst",
        "pharmaceutical",
        "inc"
    ]
}